Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 5/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.48 |
| ▸ | HTR2B | P41595 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19972025 | 0.84 | GABRA1 (0.54) | GABRA1GABRB1LMNAGABRB2SLC6A2 | |
| SCHEMBL1243033 | 0.82 | GABRA1 (0.52) | GABRA1GABRB1LMNAGABRB2SLC6A2 | |
| SCHEMBL1494556 | 0.81 | GABRA1 (0.56) | GABRA1GABRB1LMNAGABRB2SLC6A2 | |
| SCHEMBL6542243 | 0.79 | POLB (0.42) | GABRA1GABRB1LMNAGABRB2SLC6A2 | |
| SCHEMBL366229 | 0.77 | GABRA1 (0.52) | GABRA1GABRB1LMNAGABRB2SLC6A2 | |
| SCHEMBL3359993 | 0.76 | POLB (0.48) | LMNATSHRHPGDTRPA1POLB | |
| SCHEMBL9556357 | 0.76 | GABRA1 (0.50) | GABRA1GABRB1LMNAGABRB2SLC6A2 | |
| SCHEMBL30411767 | 0.76 | GABRA1 (0.50) | GABRA1GABRB1LMNAGABRB2SLC6A2 | |
| SCHEMBL1487336 | 0.76 | GABRA1 (0.50) | GABRA1GABRB1LMNAGABRB2SLC6A2 | |
| SCHEMBL2585105 | 0.75 | GABRA1 (0.68) | GABRA1GABRB1LMNAGABRB2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6969711-B2 | Cyclic diamine compounds and medicine containing the same | KOWA COMPANY, LTD. (JP) | 2005-11-29 | — | — | US | disclosed |
| US-20040038987-A1 | Novel cyclic diamine compounds and medicine containing the same | KOWA COMPANY, LTD. (JP) | 2004-02-26 | — | — | US | disclosed |
| EP-0253340-B1 | ALKYL-SUBSTITUTED BENZOXAZINORIFAMYCIN DERIVATIVE, PROCESS FOR PREPARING THE SAME AND ANTIBACTERIAL AGENT CONTAINING THE SAME | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1993-09-29 | — | — | EP | disclosed |
| CN-1018833-B | Alkyl substituted benzoxazinorifamycin derivatives | KANEGAFUCHI CHEMICAL IND (JP) | 1992-10-28 | — | — | CN | disclosed |
| US-4859661-A | Alkyl-substituted benzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1989-08-22 | — | — | US | disclosed |
| CN-87104870-A | Benzoxazinnorifamyciderivative derivative, its preparation method that alkyl replaces and contain the antiseptic-germicide of this derivative | — | 1988-02-17 | — | — | CN | disclosed |
| EP-0253340-A1 | Alkyl-substituted benzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1988-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038987-A1 | Novel cyclic diamine compounds and medicine containing the same | LCAT, ACAT2, ACAT1 | GABRA1 3225/4885GABRB1 3084/4885LMNA 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.